Empowered Patient Podcast

Greg Merril, CEO, Adaptive Phage Therapeutics describes useful viruses that host on and kill bacteria acting as nature's natural antibiotic. Phage therapy actually predates antibiotics but recent research has enabled scientist to better identify which phage will have the desired impact on specific bacteria. Greg talks about how modern phage therapy, drawing on a large collection of phage, might become the best way to treat recalcitrant, chronic infections where antibiotics have failed. Greg's father Carl Merril spent the majority of his career at NIH working on basic research on phage beginning in the mid 1960s.

#phagetherapy #phage #antibiotics #viruses

APhage.com

Listen to the podcast here.

Greg Merril, CEO, Adaptive Phage Therapeutics describes useful viruses that host on and kill bacteria acting as nature's natural antibiotic. Phage therapy actually predates antibiotics but recent research has enabled scientist to better identify which phage will have the desired impact on specific bacteria. Greg talks about how modern phage therapy, drawing on a large collection of phage, might become the best way to treat recalcitrant, chronic infections where antibiotics have failed. Greg's father Carl Merril spent the majority of his career at NIH working on basic research on phage beginning in the mid 1960s.

#phagetherapy #phage #antibiotics #viruses

APhage.com

Download the transcript here.

Dr. Hartmut Ehrlich, CEO, Abivax gives an update of the French biotech's phase-2b clinical trial drug candidate ABX464 which has shown impressive results. Dr. Ehrlich discusses how this revolutionary small molecule for oral administration has shown strong anti-inflammatory effects to solve the unmet needs of patients with inflammatory conditions like ulcerative colitis, Crohn's disease, and arthritis by using the body's own immune system to fight the diseases.

@abivax #abivax #inflammation #IBD #rheum

Abivax.com

Listen to the podcast here

Dr. Hartmut Ehrlich, CEO, Abivax gives an update of the French biotech's phase-2b clinical trial drug candidate ABX464 which has shown impressive results. Dr. Ehrlich discusses how this revolutionary small molecule for oral administration has shown strong anti-inflammatory effects to solve the unmet needs of patients with inflammatory conditions like ulcerative colitis, Crohn's disease, and arthritis by using the body's own immune system to fight the diseases.

@abivax #abivax #inflammation #IBD #rheum

Abivax.com

Download the transcript here

Michelle Sexton Naturopathic Doctor is an assistant adjunct professor in the department of anesthesiology in the UCSD health system. She also has a clinical naturopathic and holistic practice working with patients who are looking to understand the underlying cause of disease and to treat the cause rather than the symptom. Drawing on her understanding of the endocannabinoid system, Michelle explains how THC, the primary compound of cannabis, can be effective for treating pain, seizures, and opioid addiction.

#cannabis #endocannabinoid #painmanagement

MSextonND.com

Listen to the podcast here

Michelle Sexton Naturopathic Doctor is an assistant adjunct professor in the department of anesthesiology in the UCSD health system. She also has a clinical naturopathic and holistic practice working with patients who are looking to understand the underlying cause of disease and to treat the cause rather than the symptom. Drawing on her understanding of the endocannabinoid system, Michelle explains how THC, the primary compound of cannabis, can be effective for treating pain, seizures, and opioid addiction.

#cannabis #endocannabinoid #painmanagement

MSextonND.com

Download the transcript here

Jeff Wolf, CEO, Heat Biologics describes the vaccine platform Heat has developed originally for oncology and their licensing agreement with the University of Miami to use the same vaccine approach for NIH-funded studies against Zika, malaria, and HIV against the Coronavirus. Their novel approach is using allogeneic off-the-shelf contained cell based therapy that delivers a potent cell protein called GP96 that secretes antigens to activate T cells to attack the COVID-19 virus.

#Coronavirus. #COVID19

HeatBio.com

Listen to the podcast here

Jeff Wolf, CEO, Heat Biologics describes the vaccine platform Heat has developed originally for oncology and their licensing agreement with the University of Miami to use the same vaccine approach for NIH-funded studies against Zika, malaria, and HIV against the Coronavirus. Their novel approach is using allogeneic off-the-shelf contained cell based therapy that delivers a potent cell protein called GP96 that secretes antigens to activate T cells to attack the virus.

#Coronavirus #COVID19

HeatBio.com

Download the transcript here

Jovan Stevovic, founder, Chino.io provides a window into the challenges of protecting health data, how the European Union is handling security and privacy of healthcare data, and the high standards set by the new GDPR regulation. Jovan also addresses the need by researchers for population health data, why the European insurance companies are mandated to provide insurance to everyone and the need to educate all stakeholders involved in healthcare and health to protect against inside and outside invasion.

@chino_API

Chino.io

Listen to the podcast here.

Jovan Stevovic, founder, Chino.io provides a window into the challenges of protecting health data, how the European Union is handling security and privacy of healthcare data, and the high standards set by the new GDPR regulation. Jovan also addresses the need by researchers for population health data, why the European insurance companies are mandated to provide insurance to everyone and the need to educate all stakeholders involved in healthcare and health to protect against inside and outside invasion.

@chino_API

Chino.io

Download the transcript here